缺血性卒中静脉溶栓后的长期生存:倾向评分匹配队列随访长达10年
基于南伦敦卒中登记库2005年1月至2015年12月首次卒中的缺血性卒中患者,采用倾向评分按1:2匹配溶栓组与对照组,主要结局为10年生存。溶栓组中位生存5.72年高于对照组4.98年,10年死亡风险降低37%(HR=0.63,95%CI 0.48-0.82),5年功能独立(Barthel指数≥90)的OR为3.76(95%CI 1.22-13.34)。
要点
- 溶栓组中位生存5.72年,对照组4.98年,分层log-rank检验P<0.001。
- 10年死亡风险降低37%(HR=0.63,95%CI 0.48-0.82)。
- 5年功能独立(Barthel指数≥90)OR=3.76(95%CI 1.22-13.34)。
核心结论
- 静脉阿替普酶溶栓与缺血性卒中后长期生存和功能状态改善相关。
研究设计与样本
- 基于人群的南伦敦卒中登记库,纳入2005年1月至2015年12月首次卒中的缺血性卒中患者。
- 采用倾向评分按1:2匹配溶栓组与对照组,匹配变量为人口学和临床协变量。
- 从2052例缺血性卒中中,246例溶栓患者匹配492例对照。
- 中位随访时间5.45年(四分位距4.56)。
主要发现
- 溶栓组中位生存5.72年,对照组4.98年,分层log-rank检验P<0.001。
- 5年预防1例死亡需治疗人数为12,10年为20。
- Cox回归显示10年死亡风险降低37%(HR=0.63,95%CI 0.48-0.82)。
- 引入乘法交互项后,3小时内到院者10年死亡风险降低42%(HR=0.58,95%CI 0.40-0.82)。
- 10年期间溶栓组平均比对照组多存活1年。
关键数值与推荐
- 5年功能独立定义为Barthel指数≥90。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Intravenous thrombolysis with alteplase is one of the few approved treatments for acute ischemic stroke; nevertheless, little is known about its long-term effects on survival and recovery because clinical trials follow-up times are limited. METHODS: Patients registered between January 2005 and December 2015, to the population-based South London Stroke Register of first-ever strokes. Propensity score was used to match thrombolyzed and control cases to a 1:2 ratio by demographical and clinical covariates. The primary outcome was survival up to 10 years using Kaplan-Meier estimates, Cox proportional hazards, and restricted mean survival time. Secondary outcomes included stroke recurrence and functional status (Barthel Index and Frenchay Activities Index scores) at 5 years. RESULTS: From 2052 ischemic strokes, 246 treated patients were matched to 492 controls. Median follow-up time 5.45 years (interquartile range, 4.56). Survival was higher in the treatment group (median, 5.72 years) compared with control group (4.98 years, stratified log-rank test <0.001). The number needed to treat to prevent 1 death at 5 years was 12 and 20 at 10 years. After Cox regression analysis, thrombolysis reduced risk of mortality by 37% (hazard ratio, 0.63; 95% confidence interval [CI], 0.48-0.82) at 10 years; however, after introducing a multiplicative interaction term into the model, mortality risk reduction was 42% (hazard ratio, 0.58; 95% CI, 0.40-0.82) at 10 years for those arriving within 3 hours to the hospital. On average, in a 10-year period, treated patients lived 1 year longer than controls. At 5 years, thrombolysis was associated with independence (Barthel Index≥90; odds ratio, 3.76; 95% CI, 1.22-13.34) and increased odds of a higher Frenchay Activities Index (proportional odds ratio, 2.37; 95% CI, 1.16-4.91). There was no difference in stroke recurrence. CONCLUSIONS: Thrombolysis with intravenous alteplase is associated with improved long-term survival and functional status after ischemic stroke.
引用
- Muruet W, Rudd A, Wolfe CDA, et al. Long-Term Survival After Intravenous Thrombolysis for Ischemic Stroke: A Propensity Score-Matched Cohort With up to 10-Year Follow-Up. Stroke. 2018. PMID: 29440582. doi:10.1161/STROKEAHA.117.019889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。